Frank David 11/30/22 Frank David 11/30/22

Red flags in biotech press releases

Learn the classic signs of spin and misdirection in biotech PR about clinical trial results.

Frank David 2/15/22 Frank David 2/15/22

How risky is that biotech trial?

A framework to more methodically assess clinical development probability of success (POS).

Frank David 2/28/20 Frank David 2/28/20

Our data shed light on disparities in clinical study access across U.S. urban areas.

Frank David 5/1/19 Frank David 5/1/19

R&D portfolio strategy is so … unstrategic. Together with Navigant’s Greg Belogolovsky, we have some ideas to fix it.

Frank David 1/2/18 Frank David 1/2/18

FDA approved 46 new drugs so far in 2017. But are they the drugs we need?

Frank David & Matthew Murphy 7/3/17 Frank David & Matthew Murphy 7/3/17

Pharma CEOs boast of trimming headcount and boosting productivity. Spoiler alert: they're not.

Frank David 5/21/17 Frank David 5/21/17

Critics claim pharma is skimping on research spending - but the data say otherwise.

Frank David 12/10/16 Frank David 12/10/16

New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.

Frank David 8/29/16 Frank David 8/29/16

There are plenty of ways to win in diagnostics - Theranos just needs to pick one.